All In Biotech

Drug Trial Radar · NCT07447102

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

A Phase II Clinical Study to Evaluate the Efficacy and Safety of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Apr 1, 2029

Study completion Apr 1, 2029

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • BC006Drug

    A 1.0 mg/kg or 0.3 mg/kg IV infusion of BC006 based on the patients weight will be administered Q2W to Week 24.

  • PlaceboDrug

    lacebo matching BC006 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI), as well as vital signs, physical examination, 12-lead ECG, and laboratory tests, etc.Time frame: From Baseline up to Week 24
  2. Absolute change in FVC (mL) from baseline in week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dragonboat Biopharmaceutical,Co.,Ltd

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.